RS51313B - Retard tablete sa hidromorfonom - Google Patents

Retard tablete sa hidromorfonom

Info

Publication number
RS51313B
RS51313B RSP-2010/0084A RSP20100084A RS51313B RS 51313 B RS51313 B RS 51313B RS P20100084 A RSP20100084 A RS P20100084A RS 51313 B RS51313 B RS 51313B
Authority
RS
Serbia
Prior art keywords
active agent
layer
hydromorphon
hydromorphone
release
Prior art date
Application number
RSP-2010/0084A
Other languages
English (en)
Inventor
Marc Zingraff
Markus Reher
Original Assignee
Acino Pharma Ag.51311
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51313(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acino Pharma Ag.51311 filed Critical Acino Pharma Ag.51311
Publication of RS51313B publication Critical patent/RS51313B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)

Abstract

Tableta sa jezgrom tablete koje se sastoji od više peleta, koje sadrže aktivnu materiju, i jedne ili više farmaceutski podnošljivih pomoćnih supstanci i najmanje jednog sloja nanetog na jezgro tablete, pri čemu pelete, koje sadrže aktivnu materiju, sadrže hidromorfon kao aktivnu materiju ili njegovu so ili solvat i imaju sledeću strukturu:a) inertno jezgro,b) sloj aktivne materije nanet na inertno jezgro,c) sloj nanet na sloj aktivne materije koji odlaže oslobadjanje aktivne materije, id) još jedan sloj aktivne materije na sloju, koji odlaže oslobadjanje aktivne materije.Prijava sadrži još 9 patentnih zahteva.
RSP-2010/0084A 2007-11-09 2007-11-09 Retard tablete sa hidromorfonom RS51313B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07021788A EP2057984B1 (de) 2007-11-09 2007-11-09 Retardtabletten mit Hydromorphon

Publications (1)

Publication Number Publication Date
RS51313B true RS51313B (sr) 2010-12-31

Family

ID=39272211

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2010/0084A RS51313B (sr) 2007-11-09 2007-11-09 Retard tablete sa hidromorfonom

Country Status (15)

Country Link
US (1) US20100247647A1 (sr)
EP (3) EP2057984B1 (sr)
JP (1) JP2011503017A (sr)
AT (2) ATE455538T1 (sr)
AU (1) AU2008324466A1 (sr)
CA (1) CA2704646C (sr)
DE (1) DE502007002695D1 (sr)
DK (2) DK2057984T3 (sr)
ES (2) ES2337935T3 (sr)
HR (1) HRP20100157T1 (sr)
PL (1) PL2057984T3 (sr)
PT (1) PT2057984E (sr)
RS (1) RS51313B (sr)
SI (1) SI2057984T1 (sr)
WO (1) WO2009059701A2 (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
AU2010339882B2 (en) 2009-12-17 2016-10-27 Cima Labs Inc. Abuse-resistant formulations
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク． メトプロロールを含むアルコール耐性持続放出性経口剤形
EP2446882B8 (de) * 2010-10-28 2014-02-12 Acino Pharma AG Arzneimittel mit dem Wirkstoff Hydromorphon mit verbesserter Lagerstabilität
EP2606879A1 (en) 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
WO2014034929A1 (ja) * 2012-09-03 2014-03-06 第一三共株式会社 ヒドロモルフォン塩酸塩含有の経口用徐放性医薬組成物
CA2795324C (en) * 2012-11-09 2015-07-14 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
CA2970065A1 (en) 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
CN111432804A (zh) 2017-11-27 2020-07-17 帝斯曼知识产权资产管理有限公司 冻干的多微粒固体剂型
TW201943410A (zh) 2018-04-10 2019-11-16 荷蘭商帝斯曼知識產權資產管理有限公司 具有彈性結構之多顆粒固體劑型
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
DE19927688A1 (de) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
WO2004112746A1 (en) * 2003-06-26 2004-12-29 Korea Research Institute Of Chemical Technology Controlled release-drug delivery system for oral administration
WO2005034859A2 (en) * 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20070104789A1 (en) * 2005-11-04 2007-05-10 Donald Spector Gastro-resistant and ethanol-resistant controlled-release formulations comprising hydromorphone
CN101410095B (zh) * 2006-03-06 2015-07-01 波曾公司 施用组合药物的剂型

Also Published As

Publication number Publication date
CA2704646A1 (en) 2009-05-14
EP2425822A1 (de) 2012-03-07
PT2057984E (pt) 2010-03-10
PL2057984T3 (pl) 2010-05-31
DE502007002695D1 (de) 2010-03-11
SI2057984T1 (sl) 2010-04-30
DK2057984T3 (da) 2010-05-03
EP2057984B1 (de) 2010-01-20
HRP20100157T1 (hr) 2010-04-30
EP2057984A1 (de) 2009-05-13
ES2337935T3 (es) 2010-04-30
DK2217210T3 (da) 2012-02-13
ATE455538T1 (de) 2010-02-15
WO2009059701A2 (de) 2009-05-14
CA2704646C (en) 2016-04-05
JP2011503017A (ja) 2011-01-27
ATE536862T1 (de) 2011-12-15
WO2009059701A3 (de) 2009-07-16
US20100247647A1 (en) 2010-09-30
EP2217210B1 (de) 2011-12-14
EP2425822B1 (de) 2012-12-19
ES2374690T3 (es) 2012-02-21
EP2217210A2 (de) 2010-08-18
AU2008324466A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
SI2057984T1 (sl) Retardne tablete s hidromorfonom
DK1631251T3 (da) Tablet til forsinket frigørelse med defineret kernegeometri
WO2008039291A3 (en) Dosage forms for tamper prone therapeutic agents
HK1132175A1 (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
WO2009113703A3 (en) Orally-disintegrating solid preparation
WO2012085657A3 (en) Tamper resistant solid oral dosage forms
MX2010003304A (es) Suplemento alimenticio granular.
MX2010006694A (es) Formulacion de liberacion controlada, preventiva de mal uso.
AR049062A1 (es) Formulacion de tableta revestida que contiene un inhibidor dpp4, como saxagliptina, y metodo
WO2011060256A3 (en) Bilayer tablet formulations
WO2009025063A1 (ja) 離型用シート
ZA200803502B (en) Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof
WO2007072495A3 (en) Coated tablets having prolonged gastric retention
DE602006004610D1 (de) Carvedilol enthaltende pharmazeutische zusammensetzung mit kontrollierter freisetzung
MX2012007365A (es) Composiciones farmaceuticas de liberacion lenta de iloperidona.
EP2589492A4 (en) SUPPORT FILM FOR RIBBON MATERIAL AND RIBBON MATERIAL
WO2011047277A3 (en) Release of agents from cells
WO2011090725A3 (en) Gastroretentive solid oral dosage forms with swellable hydrophilic polymer
MX2009013054A (es) Composicion farmaceutica que comprende un sustrato y un revestimiento que contiene un ingrediente activo y alcohol polivinilico.
WO2011093612A3 (en) Oral complex composition comprising pseudoephedrine and levocetirizine
WO2012028922A8 (en) Controlled release pharmaceutical compositions of milnacipran
MX2021014339A (es) Preparacion de granulo inhibidor de parp y proceso de preparacion del mismo.
WO2008060275A3 (en) Systems and methods for hydrogen loading and generation of thermal response
WO2008012687A3 (en) Tape supply and tape cassette
GEU20061312Y (en) Tablet of moxifloxacin